Europe Dietary Supplements Market Worth $33.80 Billion by 2027; Prominent Companies Such as Archer Daniels and Nestle to Focus on Widening Their Business Horizons: Fortune Business Insights™

Europe Dietary Supplements Market Worth $33.80 Billion by 2027; Prominent Companies Such as Archer Daniels and Nestle to Focus on Widening Their Business Horizons: Fortune Business Insights™

  • February 23, 2021

Pune, India, Feb. 23, 2021 (GLOBE NEWSWIRE) — The Europe dietary supplements market size is projected to reach $33.80 Billion by 2027, exhibiting a CAGR of 9.3% during the forecast period. The rapid spread of the coronavirus across Europe has brought to the fore the importance of dietary supplements in the recent months, states Fortune Business Insights™ in its report, titled Europe Dietary Supplements Market Size, Share & COVID-19 Impact Analysis, By Type (Vitamins, Minerals, Enzymes, Fatty Acids, Proteins, and Others), Form (Tablets, Capsules, Powder, and Liquid), and Regional Forecasts, 2020 – 2027”. Dietary supplements consisting of specific vitamins, proteins, and other micronutrients have been proven to be effective in strengthening the immune system’s response to the COVID infection. A study conducted by researchers from the University Medical Center in the Netherlands, the University of Otago in New Zealand, the University of Southampton in the UK, and the Oregon State University in the US found that vitamins C & D, and DHA, an Omega-3 fatty acid found in fish, can significantly boost immune function.

A strong immune system is critical in fighting the COVID-19 infection and as the pandemic continues its rampage across Europe, the demand for dietary supplements is set to spike in the region.

As per the report, the market value stood at $14.95 billion in 2019. It also provides the following:

  • Microscopic analysis of the various market segments;
  • Tangible insights into the drivers and trends shaping the market’s growth trajectory;
  • A detailed evaluation of the challenges facing the market; and
  • An exhaustive study of the regional dynamics and competitive milieu of the market.

List of Key Players Covered in the Europe Dietary Supplements Market Report:

  • Suntory Holdings Ltd. (Tokyo, Japan)
  • Danone S.A. (Paris, France)
  • Herbalife Nutrition Ltd. (California, United States)
  • GlaxoSmithKline plc (Brentford, United Kingdom)
  • Amway Corp (Michigan, United States)
  • Pfizer Inc. (New York, United States)
  • Nestle S.A. (Vevey, Switzerland)
  • Glanbia Nutritionals (Chicago, United States)
  • Archer Daniels Midland Company (Chicago, United States)
  • Abbott Laboratories (Chicago, United States)

Get Sample PDF Brochure with Impact of COVID19:

Key Market Driver

Changing Demographics in Europe to Feed Market Growth

Europe, according to the UN’s Population Division, was the first region to enter the period of demographic transition, characterized by lower fertility and improved longevity. The UN states that in 2017, nearly 20% of Europe’s population was aged 60 and above and by 2050, this is expected to reach 35%. This presents attractive opportunities for players in the dietary supplements market of Europe as older people need to consume supplementary food items to maintain their health and energy. For example, the National Institute of Aging in the US recommends sufficient intake of calcium for people over the age of 50 for maintaining bone density as bone loss can lead to fractures in older persons. Similarly, physicians commonly recommend old people to increase their intake of vitamin B6, which is present in bananas, potatoes, fortified cereals, and chicken breast, as it is necessary to form red blood cells. Thus, the European dietary supplements market growth is anticipated to gain impetus as the continent’s geriatric population rises.

Regional Insights

Improving Adoption Rate of Food Supplements to Surge the Regional Market

Rising awareness about the multiple benefits of dietary supplements is improving the adoption rate of these products across Europe. To a large extent, this is attributable to the changing perception of food supplement products among consumers in countries such as Belgium, Austria, Denmark, and Greece. The demand for specialized supplements is also growing in the continent, and companies in the region are extensively utilizing e-commerce platforms to broaden their reach regionally as well as internationally.

Among countries, Italy is expected to dominate the Europe dietary supplements market share during the forecast period on account of supportive policy framework for herbal food supplements in the country. In 2019, the region’s market size was at USD 2.99 billion. On the other hand, the UK is anticipated to display a remarkable CAGR of 9.69% in the forthcoming years.

Competitive Landscape

Research-based Collaborations to Emerge as Hallmark Feature of Competition

Leading players in the Europe dietary supplements market are actively collaborating with diverse organizations, institutions, and companies to enhance their research capacities. This is allowing them to widen their offerings and develop products for specific consumers. Additionally, companies are leveraging digital platforms to boost sales and strengthen distribution networks.

Browse Detailed Summary of Research Report with TOC:

Detailed Table of Content:

  • Introduction
    • Research Scope
    • Market Segmentation
    • Research Methodology
    • Definitions and Assumptions
  • Executive Summary
  • Market Dynamics
    • Drivers, Restraints
    • Market Opportunities
    • Emerging Trends
  • Key Insights
    • Overview of the Parent/ Related Markets
    • Supply Chain Analysis
    • Industry SWOT Analysis
    • Analysis on Technological Advancements Analysis
    • Recent Industry Developments- Policies, Partnerships, New Product Launches, and Mergers & Acquisitions
  • Europe Dietary Supplements Market Analysis, Insights and Forecast, 2016–2027
    • Key Findings / Summary
    • Market Size Estimates and Forecasts
      • By Type (Value)
        • Vitamins
        • Minerals
        • Enzymes
        • Fatty Acids
        • Proteins
        • Others
      • By Form (Value)
        • Tablets and Capsules
        • Liquids
        • Powder
      • By Country
        • Germany
        • France
        • Italy
        • Spain
        • U.K.
        • Rest of Europe
  • Germany Dietary Supplements Market Analysis, Insights and Forecast, 2016–2027
    • Key Findings / Summary
    • Market Size Estimates and Forecasts
      • By Form (Value)
        • Tablets and Capsules
        • Liquids
        • Powder

TOC Continued…!

Speak to Our Expert:

Key Industry Developments:

  • February 2020: Nestle Health Science signed a long-term agreement with VALBIOTIS, a French health R&D company, to develop and commercialize TOTUM-63. Conceived to lower the risk of development of Type 2 Diabetes in pre-diabetic persons, the product features an innovative combination of five plant extracts.
  • November 2019: Royal DSM completed its takeover of AVA, a US-based nutrition platform, strengthening its portfolio of health and wellness products and services. AVA is an AI-based digital health platform that provides adaptive nutrition recommendations and delivers live coaching to customers.


Have a Look at Related Research Insights:

Plant based Protein Supplements Market Size, Share & COVID-19 Impact Analysis, By Type (Soy Protein, Pea Protein & Wheat Protein), Distribution Channel (Mass Merchandisers, Pharmacies/Drugstores, Specialty Stores, Online Retail, and Others), and Regional Forecast, 2020-2027

Natural Vitamin E Market Size, Share & Industry Analysis, By Type (Tocopherols, and Tocotrienols), Application (Dietary Supplements, Food and Beverages, Cosmetics, and Others), and Regional Forecasts 2019-2026

Southeast Asia Dietary Supplements Market Size, Share & Industry Analysis, By Type (Vitamins, Minerals, Enzymes, Fatty Acids, Proteins, and Others), Form (Tablets and Capsules, Powder, and Liquid), and Regional Forecasts, 2019 – 2026

EPA & DHA Market Size, Share & Industry Analysis, By Type (Eicosapentaenoic Acid (EPA), Docosahexaenoic Acid (DHA)), By Source (Algae, Fish, Krill, Others), By Application (Dietary Supplements, Functional Food & Beverages, Infant Formulae, Pharmaceuticals, Others) and Regional Forecast, 2021-2028

About Us:

Fortune Business Insights™ offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them to address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.

Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data.

At Fortune Business Insights™, we aim at highlighting the most lucrative growth opportunities for our clients. We, therefore, offer recommendations, making it easier for them to navigate through technological and market-related changes. Our consulting services are designed to help organizations identify hidden opportunities and understand prevailing competitive challenges.

Contact Us:

Fortune Business Insights™ Pvt. Ltd.

308, Supreme Headquarters,

Survey No. 36, Baner,

Pune-Bangalore Highway,

Pune – 411045, Maharashtra, India.


US: +1 424 253 0390

UK: +44 2071 939123

APAC: +91 744 740 1245

Fortune Business Insights™

LinkedIn | Twitter | Blogs

Read Press Release:

Dr. Tom Buckley

7 Tips to Boost Your Immune System and why it matters for business > CEOWORLD magazine

  • February 13, 2021

A healthy and fully functioning immune system is vital to running a business. It recognises and combats threats, like bacteria and viruses including the COVID-19 virus and maintains health during times of increased stress.

But what exactly is the immune system and what can you do to keep it healthy?   The short answer is “a healthy functioning immune system lives in a healthy body.”

The immune system is a collection of structures and processes within the body. It is essentially our second line defence system, after our skin.

Here are 7 strategies for maintaining a healthy immune system. 

  1. RECOVERY: Running a small business can require long hours making recovery seem like a luxury you can’t afford. However, to optimise immunity and remain able to work optimally, it is critical to focus on recovery, especially to ensure adequate quality sleep.

    Sufficient quality sleep increases our levels of lymphocytes, the cells that fight against intracellular pathogens, for example, virus-infected cells such as the flu. Reduced sleep results in increased circulating stress hormones such as cortisol, higher inflammation and contributes to immune imbalance, making you more susceptible to infections.

  2. FUEL: When on the run, you may not always be able to eat at regular hours or find healthy food readily available. The effects of eating well most of the time however are significant. To optimise your immunity, it is essential to look after your gut bacteria by consuming a balanced, low processed diet and also consider including prebiotics and probiotics from food. A healthy gut is essential to strong immunity, health and wellbeing. A balanced diet should include portions of plant-based foods, especially leafy greens, and whole grains to ensure intake of adequate prebiotics. Prebiotics are essential for a healthy gut and also include fermented foods such as yogurt and kombucha.

    Alcohol intake should be moderate and not exceed national guidelines of 2 units for males and 1 for females daily, as higher levels can depress your immune function as can eating foods high in sugar.

  3. MOVE: Making time for physical activity may be challenging when running a small business. Physical activity has been shown to have numerous benefits to the body but from an immune perspective, it increases circulation of the immune cells in the body, making it more likely that they can react quickly where needed in the body.

    Physical activity also boosts the production of a type of white cell called macrophages, which help to attack invading bacteria or viruses that can trigger upper respiratory tract infections.

    Physical activity temporarily raises body temperature, which has a role in preventing or reducing bacterial growth. However, keep exercise at moderate levels during times of stress as introducing high intensity has a temporary adaptation effect on the immune system.

  4. THINK: Stress essentially weakens our immune system. When stressed, the immune system’s ability to fight off pathogens is greatly reduced, as the stress hormone cortisol can suppress the effectiveness of the immune system by lowering lymphocytes.

    Stress can also have an indirect effect on our immune system as we are more likely to engage in unhealthy behavioural coping strategies, such as increasing alcohol intake, tobacco smoking, eating more processed food and sugar.

    At a time when emotions can be high for a small business owner, not getting stressed can be easier said than done. However, stress management techniques that do help combat stressors include staying physically active, spending some time outdoors in nature, maintaining social contact with family and friends, limiting screen time, and introducing mindfulness and/ or meditation to your daily routine (try Insight Timer or Headspace).

  5. PLAY: When is the last time you remember truly playing and having fun?

    Remember when we used to run around as kids and play? Research has shown that play, especially outdoor play, is associated with a stronger immune system, resistance to allergies and better overall health. Play and regular doses of fun really do keep us healthy.

    A good belly laugh also makes us feel better. Research shows that laughter promotes diaphragmatic breathing (diaphragm fluttering up and down at a very quick rate) necessary to create a strong negative pressure and increased flow of lymphatic fluid. This means more immune cells, specifically lymphocytes are produced. So laughter really is good medicine.

  6. CONNECT: Many small business owners report feeling isolated, especially during times of increased workload and uncertainty. Isolation is as toxic to our health and wellbeing as smoking a packet of cigarettes daily. The mechanism is not fully understood but is believed to be related to the expression of genes that play a role in causing inflammation and a decrease in expression of genes involved in antiviral responses. Conversely, studies have shown that social contact and laughter have a measurable effect on immune function for several hours. This is a result of decreased stress hormones such as adrenaline and cortisol, which have wide-ranging effects on the nervous and immune systems.
    Essential to optimal immunity is personal hygiene, especially hand washing. Keeping hands clean is one of the most important steps we can take to avoid getting sick and spreading germs to others. Many diseases and conditions are spread by not washing hands with soap and clean, running water. The Centres for Disease Control and Prevention (CDC) recommend hand washing:

    – Before and after handling or eating food.
    – After sneezing, coughing or blowing your nose.
    – After shaking hands with another person.
    – After using the bathroom.
    – After touching an animal or handling animal waste.
    – After using public transportation.
    – After handling garbage.

Written by Dr. Tom Buckley. Have you read?
World’s Best Countries For Raising Kids.
World’s Most Entrepreneurial Countries.
World’s Best Countries to Headquarter Multinational Corporations (MNCs).

Chronic Covid-19 and Convalescent Plasma May Boost Mutation Risk

Chronic Covid-19 and Convalescent Plasma May Boost Mutation Risk

  • February 6, 2021
Fresh plasma from Covid-19 convalescents.

Photographer: Omar Marques/Getty Images

British doctors who spent 102 days treating a cancer survivor for Covid-19 documented how the virus mutated after the man was treated with convalescent plasma.

The case study suggests the use of blood plasma donated from Covid-19 survivors may have put enough pressure on the virus to force it to evolve. The result: Less susceptibility to immune system antibodies that normally fight off infection, according to the report published Friday in the journal Nature.

While the convalescent plasma didn’t seem to harm the patient, it offered no clear benefit, said senior author Ravindra Gupta, a professor of clinical microbiology at the Cambridge Institute of Therapeutic Immunology and Infectious Disease. It should be used cautiously in people with chronic immune conditions, he said, preferably in clinical trials or carefully controlled settings.

The report also suggests that numerous mutations may be emerging among patients who have both compromised immune systems and chronic infections.

“When the virus has a chance to sit in one person for a long time and replicates for weeks and months, it learns how to fight the immune system,” Gupta said. It’s all about “pressure on the virus.”

The patient didn’t develop the exact variant that’s now become the dominant form of the virus circulating in the U.K., the report said, but it did have certain elements in common. “It just illustrates that someone like him is probably patient zero,” Gupta said.

Slow Mutations

Overall, Covid-19 is mutating relatively slowly. That’s because it is a fast-moving virus giving it little time to evolve. In this case, however, the patient and his doctors fought the virus for 102 days from the time he was diagnosed until he died, Gupta said.

The patient was diagnosed with Covid-19 at a local hospital in the spring of 2020, when the first wave of the virus was reaching crisis levels in the U.K. He was subsequently brought to Cambridge University Hospitals for more intensive care.

The team there tested him twice a week to see if the treatments he was receiving, including Gilead Sciences Inc.’s remdesivir, were reducing his viral load. They were not.

Genetic Profiling

At the same time, the samples were being sent for genetic profiling. That resulted in a snapshot of the virus mutating over time, allowed the researchers to hone in on where, how and when the pathogen changed as the months progressed.

There were few changes in the virus after he received two courses of remdesivir in the first two months, according to the researchers. However, after convalescent plasma was administered, there were large, dynamic virus population shifts, including in the key spike protein, which the virus uses to latch on to and infect healthy cells.

The variants then presented evidence of reduced susceptibility to neutralizing antibodies that normally control the virus.

Large Study

The case study comes almost a month after a large, national study in the U.K. examining convalescent plasma as a therapy was ended after a finding that the treatment touted by U.S. President Donald Trump doesn’t work.

The University of Oxford research was part of a clinical trial named Recovery that’s investigating different Covid-19 treatments. The study’s other arms are ongoing.

The results come after more than 100,000 Americans have been treated with convalescent plasma after its use was authorized by U.S. regulators on an emergency basis.

Study: Russia's Sputnik V vaccine appears safe, effective

Study: Russia’s Sputnik V vaccine appears safe, effective

  • February 2, 2021

MOSCOW — Russian scientists say the country’s Sputnik V vaccine appears safe and effective against COVID-19, according to early results of an advanced study published in a British medical journal.

The news is a boost for the shot that is increasingly being purchased by nations around the world who are desperate to stop the devastation caused by the pandemic.

“But the outcome reported here is clear,” British scientists Ian Jones and Polly Roy wrote in an accompanying commentary. “Another vaccine can now join the fight to reduce the incidence of COVID-19.”

The Sputnik V vaccine was approved by the Russian government with much fanfare on Aug. 11. President Vladimir Putin personally broke the news on national television and said that one of his daughters had already been vaccinated with it. At the time, the vaccine had only been tested in several dozens of people.

Some early results were published in September, but participants had only been followed for about 42 days and there was no comparison group.

The latest study is based on research involving about 20,000 people over age 18 at 25 hospitals in Moscow between September and November, of whom three-quarters got two doses of the Russian vaccine 21 days apart and the remainder got placebo shots.

The most commonly reported side effects were flu-like symptoms, pain at the injection site and fatigue. Serious side effects were rare in both groups and four deaths were reported in the study, although none were considered to be the result of the vaccine.

The study included more than 2,100 people over age 60 and the vaccine appeared to be about 92% effective in them. The research is ongoing but in December, Russia’s Health Ministry said it would cut the size of the study from the expected 40,000 to about 31,000 volunteers that have already enrolled. Developers of the vaccine cited ethical concerns about using placebo shots.

Some experts say that approach may explain why the Russian vaccine seems to have produced a better immune response than the AstraZeneca vaccine, which has a reported efficacy rate of about 60 to 70%.

“This aims to drive higher immune responses to the target ‘spike’ by using two slightly different jabs,” said Alexander Edwards, an associate professor in biomedical technology at Britain’s University of Reading.

He said if you have two identical shots, it’s possible the immune system doesn’t get as big a boost from the second injection.

He added that, because the Russian vaccine is made using a tested technology, it should be possible to scale up manufacturing.

Sputnik V began being rolled out in a large-scale vaccination campaign in Russia in December, with doctors and teachers the first in line to get the shot. Last month, Putin ordered the effort to be expanded and for mass immunizations to start.

In early January, the Russian Direct Investment Fund that bankrolled the jab said that over 1 million Russians have already been vaccinated with the domestically developed shot. Some Russian media questioned the number and suggested that the rollout has been much slower, with many Russian regions reporting small numbers of vaccinations.

Outside Russia, Sputnik V has received authorization in over a dozen countries, according to the fund — including former Soviet republics of Belarus, Armenia and Turkmenistan; Latin American nations including Argentina, Bolivia and Venezuela; some African nations as well as Serbia, Iran, Palestine and UAE.

In the European Union, the shot has received initial authorization in Hungary and is still subject to final approval by the country’s National Public Health Center.

Batches of the vaccine have already been supplied to six countries. In all, more than 50 countries submitted applications for 2.4 billion doses, a RDIF spokesman told The Associated Press.

Algeria will begin producing the Sputnik V vaccine “within the coming weeks,” according to Kamel Mansouri, the head of Algeria’s national agency for pharmaceuticals.

The first batch of 50,000 doses of Sputnik V was flown to Algeria from Russia on Thursday, a tenth of what had been previously announced by the North African government. A cargo of 50,000 AstraZeneca doses arrived on Monday.

Mansouri said Algeria and Russia were in advanced discussions over Sputnik V and the vaccine would be manufactured at the government-owned SAIDAL facility.

“It is time that Algeria, a country that imports vaccine, be able to produce it on site to respond to the needs of the vaccination campaign, and to export in a second phase,” he said Tuesday on national television.


Cheng reported from Toronto. Associated Press writer Lori Hinnant in Paris contributed to this report.

Moderna working on booster shots for South African strain

Moderna working on booster shots for South African strain

  • January 25, 2021

Moderna said Monday it’s accelerating work on a Covid-19 booster shot to guard against the recently discovered variant in South Africa.

The company’s researchers said its current coronavirus vaccine appears to work against the two highly transmissible strains found in the U.K. and South Africa, although it looks like it may be less effective against the latter.

The two-dose vaccine produced an antibody response against multiple variants, including B.1.1.7 and B.1.351, which were first identified in the U.K. and South Africa, respectively, according to a Moderna study conducted in collaboration with the National Institute of Allergy and Infectious Diseases. The study has not yet been peer reviewed.

The vaccine generated a weaker immune response against the South African strain, but the antibodies remained above levels that are expected to be protective against the virus, the company said, adding the findings may suggest “a potential risk of earlier waning of immunity to the new B.1.351 strains.”

“Out of an abundance of caution and leveraging the flexibility of our mRNA platform, we are advancing an emerging variant booster candidate against the variant first identified in the Republic of South Africa into the clinic to determine if it will be more effective to boost titers against this and potentially future variants,” Moderna CEO Stephane Bancel said in a statement.

Shares of Moderna were up more than 10% in morning trading after the announcement.

Paul Offit, director of the Vaccine Education Center at Children’s Hospital of Philadelphia, said he’s glad Moderna is preparing for the possibility that the virus could mutate enough to evade the protection of the current vaccines. He added the ultimate goal of the vaccine is to prevent severe infections and keep people out of the hospital.

“This is not a problem yet,” said Offit, also a member of the FDA’s Vaccines and Related Biological Products Advisory Committee. “Prepare for it. Sequence these viruses. Get ready just in case a variant emerges, which is resistant” to the vaccine.

On Thursday, White House health advisor Dr. Anthony Fauci said new data showed that the Covid-19 vaccines currently on the market may not be as effective in guarding against new, more contagious strains of the coronavirus. Some early findings that were published in the preprint server bioRxiv indicate that the South Africa variant can evade the antibodies provided by some coronavirus treatments.

The news also comes after the Centers for Disease Control and Prevention said earlier this month that the U.K. variant could become the dominant strain in the U.S. by March. “It is highly likely there are many variants evolving simultaneously across the globe,” Jason McDonald, a spokesman for the CDC, said in an email to CNBC at the time.

The Food and Drug Administration authorized Moderna’s vaccine for people who are 18 years old and older in December.

Moderna’s vaccine, like Pfizer’s, uses messenger RNA, or mRNA, technology. It’s a new approach to vaccines that uses genetic material to provoke an immune response. Late-stage clinical trial data published in November shows Moderna’s vaccine is more than 94% effective in preventing Covid, is safe and appears to fend off severe disease. To achieve maximum effectiveness, the vaccine requires two doses taken four weeks apart.

Bancel told CNBC that Moderna’s vaccine will be protective against the South African strain in the short term, but the company doesn’t know how long that protection may last.

“What is unknowable right now is what will happen in six months, 12 months, especially to the elderly because, as you know, they have a weaker immune system,” he said during an interview with “Squawk Box.” “Because of that unknown … we decided to take into the clinic, out of an abundance of caution, a new vaccine.”

“We cannot be behind. We cannot fall behind this virus,” he said, adding the coronavirus will “keep mutating.”

– CNBC’s Noah Higgins-Dunn contributed to this report.

Vitamin sellers flagged by feds got coronavirus aid loans

Vitamin sellers flagged by feds got coronavirus aid loans

  • January 18, 2021

A trio of supplements sellers snagged millions in coronavirus relief loans last spring — all within weeks of getting dinged by the feds for questionable claims about their products, The Post has learned.

The vitamin marketers joined the rush for Paycheck Protection Program aid in early 2020, even as their sales reps angled to cash in on the pandemic, government records show. The reps claimed on social media that their shakes, teas and powders could help protect consumers from the deadly virus, according to the Federal Trade Commission.

“Instead of stockpiling toilet paper, you need to do something to help you fight the virus!” a rep for Pruvit Ventures allegedly wrote in a post accompanied by an image of the Texas-based company’s products. “Boost your immune system with our Immunity Boost Pack!”

The claims of immunity boosting caught the feds’ attention in particular: While the pitches might seem sensible to health-minded consumers, the FTC says such claims are illegal because there’s no scientific evidence to back them up.

“Any coronavirus-related prevention or treatment claims regarding such products are not supported by competent and reliable scientific evidence,” the agency wrote in warning letters to Pruvit, Total Life Changes and Zurvita on April 24. “You must immediately cease making all such claims.”

Nevertheless, nine days before the FTC fired off its warning letters, Pruvit and Total Life Changes had been approved for PPP loans totaling almost $1.7 million on April 15, according to data from the Small Business Administration, which oversees the $809 billion program.

Meanwhile, the third firm, Zurvita, won its own loan of roughly $1.4 million on May 1 — about a week after the FTC’s letter raised red flags about two of its reps’ posts hawking Zeal, its supplement packed with botanicals and vitamins.

“Want to join me in drinking Zeal to combat the Corona Virus? Contact me . . . to learn how to be your own Corona Virus Super Hero!” one Zurvita rep’s post read, according to the FTC.

Yet another relief loan worth $565,402 went to supplement seller IDLife, which also got an FTC warning in April. The agency said the company’s representatives claimed people could earn “substantial income” selling its products during the pandemic-fueled economic crisis.

None of the four companies responded to requests for comment.

The loans come as critics gripe that the PPP program, meant to keep workers on payrolls during the pandemic, has ended up aiding businesses with checkered pasts and deep pockets.

The SBA opened applications on Jan. 11 for another $284 billion in PPP money authorized last month. Officials have imposed tighter rules for the latest round — publicly traded companies can’t participate, for example — and Congress gave the SBA additional funding to conduct audits and root out fraud.

But that doesn’t change the fact that sketchy businesses got a lifeline that many small firms missed, according to Kyle Herrig, president of Accountable.US, a left-leaning good-government group that tracks coronavirus relief spending.

“Shady MLMs were showered with PPP money because the Trump administration let banks approve taxpayer-backed loans to practically anyone, even if they didn’t need it,” Herrig told The Post.

Nutrition companies make up a significant chunk of the multi-level marketing industry. Known as MLMs, such firms can walk a thin line between being considered legitimate businesses and illegal pyramid schemes. In the latter case, firms reward reps for bringing in new recruits and often pressure them into buying the products they’re supposed to be selling, according to the FTC.

There’s no evidence that any of the four companies mentioned above are pyramid schemes. But two other MLMs got PPP money despite being publicly accused by the feds of running pyramid scams, records show.

Neora, a Dallas-based seller of skin-care, weight-loss and “wellness” products, won a $2.5 million loan on April 8 — about five months after the FTC filed a lawsuit alleging that it pressed distributors to focus on recruiting new reps rather than making sales to customers.

The company also made unsubstantiated claims that one of its supplements could prevent brain diseases such as Alzheimer’s and Parkinson’s, according to the feds.

Neora — which “firmly” denies the FTC’s allegations — used the PPP money to retain its staff and cover other business expenses amid the pandemic, co-CEO Deborah Heisz said.

“As with almost every other business in the US, when the pandemic began there was a lot of uncertainty about what the future would look like and we were concerned for our approximately 90 full-time employees,” Heisz told The Post. “When the Paycheck Protection Program issued its guidelines, we reviewed them closely and determined Neora qualified for the loan.”

Vemma Nutrition Company — which got $227,500 in PPP funds — agreed to stop its pyramid-scheme practices under a 2016 settlement with the FTC. A federal court order in the case slapped the company with a staggering, $238 million penalty that was supposed to be “partially suspended” as long as Vemma paid about $470,000 and surrendered some of its assets, the agency said at the time.

Vemma did not respond to a request for comment.

Halberd Corp. Develops Medication to Boost Immune System Against SARS-CoV-2 (Covid-19) - Press Release

Halberd Corp. Develops Medication to Boost Immune System Against SARS-CoV-2 (Covid-19) – Press Release

  • January 14, 2021

JACKSON CENTER, PA / ACCESSWIRE / January 14, 2021 / Halberd Corp. (OTC PINK:HALB) announced the filing of a provisional patent application on a proprietary combination of nutritional supplements (melatonin, zinc and Vitamin D) combined with low dose Naltrexone designed to reduce the severity of Covid-19 symptoms. This proprietary combination of supplements is based on numerous peer-reviewed publications (1, 2, 3, 4, 5, 6, 7) from major medical organizations indicating that each of the ingredients contributes to reduced Covid-19 symptomology. Halberd intends to make the proprietary nutritional supplement formula portion available as an over-the-counter product as soon as possible. The prescription-based medication with the addition of low dose Naltrexone would be available after FDA approval is obtained.

Halberd will have exclusive worldwide rights to the provisional patent application, “Medication For The Reduction Of Morbidity And Mortality In Persons Infected By Sars-Cov-2 (Covid-19 Virus)”.

William A. Hartman, Chairman, President & CEO, stated, “Our scientists have formulated a specific combination of nutritional supplements which they believe, after reviewing numerous peer-reviewed medical articles and independent research, should provide a boost to the immune system to reduce the severity of Covid-19, when taken prior to contracting the disease or early in its onset. Each participating medical expert agrees that there would be no downside in the use of any of these ingredients.

We are excited about the prospects of securing immediate volume manufacturing and mass distribution sources for our products. A significant portion of the revenue from these initial products will be reinvested in expanding and accelerating our research programs and developing market readiness of follow-on products.”

To be added to Halberd’s email subscriber list, click here and submit the form.

For more information please contact:

William A. Hartman


About Halberd Corporation.

Halberd Corporation. (OTC PINK:HALB), is a publicly traded company on the OTC Market, and is in full compliance with OTC Market reporting requirements. Halberd’s Articles of Incorporation prohibit the company from issuance of convertible debt which would result in dilution. See the company’s Articles of Incorporation here.

The company holds the exclusive rights to the COVID-19 extracorporeal treatment technology provisional patent applications: “Method for Treating and Curing Covid-19 Infection;” “Method for Treating COVID-19 Inflammatory Cytokine Storm for the Reduction of Morbidity and Mortality in COVID-19 Patients;” “Method for Treating and Curing COVID-19 Infection by Utilizing a Laser to Eradicate the Virus,” “Nasal Spray To Prevent The Transmission Of Covid-19 Between Humans,” “Nasal Spray to Prevent the Transmission of Covid-19,” and “Method For Treating And Curing Covid-19 Infection By Utilizing Radiofrequency Extracorporeally To Eradicate The Virus,” “Medication For The Reduction Of Morbidity And Mortality In Persons Infected By Sars-Cov-2 (Covid-19 Virus).” Halberd also holds the exclusive rights to the underlying granted U.S. Patent 9,216,386 and U.S. Patent 8,758,287.


Safe Harbor Notice

Certain statements contained herein are “forward-looking statements” (as defined in the Private Securities Litigation Reform Act of 1995). The Companies caution that statements, and assumptions made in this news release constitute forward-looking statements and makes no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time statements are made. These statements may address issues that involve significant risks, uncertainties, estimates made by management. Actual results could differ materially from current projections or implied results. The Companies undertake no obligation to revise these statements following the date of this news release.

Investor caution/added risk for investors in companies claiming involvement in COVID-19 initiatives –

On April 8, 2020, SEC Chairman Jay Clayton and William Hinman, the Director of the Division of Corporation Finance, issued a joint public statement on the importance of disclosure during the COVID-19 crisis.

The SEC and Self-Regulatory Organizations are targeting public companies that claim to have products, treatment or other strategies with regard to COVID-19.

The ultimate impact of the COVID-19 pandemic on the Company’s operations is unknown and will depend on future developments, which are highly uncertain and cannot be predicted with confidence, including the duration of the COVID-19 outbreak. Additionally, new information may emerge concerning the severity of the COVID-19 pandemic, and any additional preventative and protective actions that governments, or the Company, may direct, which may result in an extended period of continued business disruption, reduced customer traffic and reduced operations. Any resulting financial impact cannot be reasonably estimated at this time.

We further caution investors that our primary focus and goal is to battle this pandemic for the good of the world. As such, it is possible that we may find it necessary to make disclosures which are consistent with that goal, but which may be adverse to the pecuniary interests of the Company and of its shareholders.

SOURCE: Halberd Corporation

View source version on


Wanderport Corporation Provides Business Update and Outlines Near Term Plans

  • January 13, 2021

Santa Monica, California–(Newsfile Corp. – January 13, 2021) – Wanderport Corporation (OTC PINK: WDRP), a premier producer and distributor of food, beverages and consumer products with a focus on wellness and healthy lifestyle, today announces update of its business development and outlines near term growth plans.

The Company had recently undergone evaluation of its existing business and as a result made some changes to position itself as a key solution provider with an emphasis on wellness and healthy lifestyle.

Wanderport’s main website will be redesigned and will initially consist of three divisions: coffee and tea, consumer products and healthcare. Additional divisions will be added in the future as acquisitions or mergers are made.

Coffee and Tea

The sales of Sapa coffees and teas remain strong. However, to better optimize sales, the Hemp and CBD product line will be reduced to a few best selling items. The final product line will also be repackaged and better optimized to sell online via Amazon and other venues.

The Company plans to introduce two new products, hemp matcha tea and a unique non-hemp coffee. The non-hemp coffee will have a crypto component. Details are being finalized and the product introduction will be announced before the end of this month.

In response to the increasing inquiries on CBD products, efforts to expand sales into retail channels are also being planned.

Consumer Products

Consumer products will continue to be offered through Wander Brands. The categories will be narrowed down to supplements, pain management and mental acuity products. Supplements will consist of natural or vitamins to boost immune system. Pain management products will aim at providing relief ranging from muscle soreness to arthritis to chronic pain. Mental acuity products will help with mental clarity, memory and healthy brain function.


The Company plans to form a new division that offer healthcare products and services. Initial focus will be in the areas of therapy, wellness, pain management and mental illness. The Company will leverage technology to offer solutions in telehealth and remote patient monitoring.

The Company will also work with various non-profit organizations to provide assistance in the area of cancer, Alzheimer and mental illness. Additional information regarding the healthcare initiative is forthcoming.

Online and Social Media Presence

For better communication and branding, the Company will also enhance its websites, online stores and social media presence. Redesigning of the existing sites are underway and will be updated in phases in the near future.

The Company plans to use social media more actively to provide incremental updates between major press releases.

Customer Reward Programs

The Company will enhance its customer reward program and various promotional offerings to reward loyal customers and supporters as well as to entice new customers to try its products.

The Company will also introduce a digital token as rewards for purchases. Tokens can eventually be redeemed as discount for purchases or for another token such as Bitcoin. Additional information regarding the Wanderport token and its use will be provided in the near future.

About Wanderport Corporation:

Wanderport Corporation is a premier producer and distributor of food, beverages and consumer products with a focus on wellness and healthy lifestyle. Its premium quality coffee blends are currently being sold in a growing number of boutique retail stores and small businesses in the Southern California territory. Its products are also sold online at,

For more information, please visit

Facebook: wanderportcorporation
Twitter: @wanderportcorp
Instagram: wanderportcorp

Forward Looking Statements:

Statements made herein constitute forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those stated or implied by such forward-looking statements. The potential risks and uncertainties include, among others, potential volatility in the company’s stock price, increased competition, customer acceptance of new products and services to be offered by the company, and uncertainty of future revenue and profitability and fluctuations in its quarterly operating efforts. Forward-looking statements are projections of events, revenues, income, future economics, research, development, reformulation, product performance or management’s plans and objectives for future operations. While these forward-looking statements and any assumptions upon which they are based are made in good faith and reflect current judgment regarding the direction of the business operations of Wanderport Corporation, actual results will almost always vary, sometimes materially, from any estimates, predictions, projections, assumptions or other future performance suggested in this press release.

Wanderport Corporation

Investor Relations:
Miki Takeuchi
(310) 526-8720

To view the source version of this press release, please visit

Tonic Health steps up super vitamin charge to boost immunity | City & Business | Finance

Tonic Health steps up super vitamin charge to boost immunity | City & Business | Finance

  • January 10, 2021

Its innovative powder formulations include top rated immunity defenders vitamins C and D along with zinc and plant extracts and are produced in partnership with a UK manufacturer.  Now in its second year and despite the highly volatile trading situation the brand is hoping for a £500,000 turnover in 2021 as demand for preventative health pick-me-ups grows and consumers’ respond to its unique A-list credentials.

In Tonic’s case that A stands for absorption, the beneficial elements in a product that a body actually absorbs that are a vital but often overlooked aspect of supplement taking. 

Founder and former corporate financier Sunna Van Kampen explains:

 “We are the highest dose and most natural immunity drink on the market, combining the high vitamin doses with the plant extracts which helps increase the absorption and is absolutely key to our format. This enables 90 percent take up by the body compared to tablets which is around 30 to 40 percent.” 

Years of fending off colds and seeing the shortfall in remedies, which focussed on symptom relief rather than immune system recovery, led to Van Kampen looking deep into what the science had to say and developing his own natural solutions. 

From ginger to lesser known potent ingredients such as aged garlic and reishi mushrooms, the recipes for Tonic were born.

Getting them to market took an investor group that includes New Look founder Tom Singh and £550,000 so far. Last year Tonic launched three products, including an immunity night drink that have won contracts with Boots and Holland & Barrett.

Customers are split between those who are proactive about their health and others who give the products a go because they are sick or run down.

Most popular is the daytime Elderberry & Blackcurrant drink with a whacking 1,500 mg Vitamin C hit. “We use British blackcurrants and our customers love that too,” says Van Kampen.

A new daily effervescent tablet is due next month along with a travel pack, while a further £1.5million raise he is planning will go to expanding exports with the US top of the list.

“Learn quickly,” has always been Van Kampen’s motto and he and his team of five have certainly had experience of that over the past 15 months.

The trials of smoothing out the production process came good, but like other small businesses the current challenges posed by lockdowns and Brexit are testing Tonic’s resilience in ways unimaginable a year ago.   

“Now 30 percent of our sales are direct and online. Multi-channel is the future but the present situation does not compensate for being on the big retailers’ shelves,” says Van Kampen. 

 “Smaller, lesser known brands like us get picked up when high street shoppers are browsing, not so much when surfing online. That is the particular impact of Covid on small businesses rather than larger ones.”

The extra paperwork following Brexit will need the equivalent of two or more working days a month. “Holland & Barrett sell in Ireland and for us to sell through them will require both of us having to do more admin. We are still unclear about other aspects too such as VAT. Clarity is desperately needed,” says Van Kampen, voicing problems shared by an increasing number of SMEs.

A Spanish distributor Tonic had lined up has now said it wants to wait before it receives shipments. 

“Everyone seems to be feeling they want the dust to settle,” adds Van Kampen.

When it does Tonic will be ready and recharged, aiming to recruit three more staff and settle into a new office it is now renting in central London.

“Ego goes out the window when you become an entrepreneur,” says Van Kampen. “You just have to persist.”

Chicago-Area Gyms Hopeful for Boost in Business With Start of New Year – NBC Chicago

Chicago-Area Gyms Hopeful for Boost in Business With Start of New Year – NBC Chicago

  • January 2, 2021

The pandemic has changed how and where many people exercise. 

So will the start of 2021 and peoples’ New Year’s resolutions create a boost of business for Chicago-area fitness centers already operating at limited capacity?

Mike Tenerelli, owner of CrossFit Alpha Dog in Lombard, said his gym practices social distancing, taking temperatures and disinfecting equipment.

“I’m seeing a little bit of interest with New Year’s resolutions,” Tenerelli said. “I think the next couple of days will be real telling, especially once the work week starts back up on Monday.”

Tenerelli also said while he is hesitant because the nation is still dealing with the virus, he thinks a lot of gyms will survive and new ones will open.

“It’s going to be a little bit, but I think slowly, but surely with the vaccine and people understanding the virus more, I think optimism is on the climb and I hope 2021 is kind of the start of that,” Tenerelli said.

Fitness experts, however, said it’s not just about getting people back inside gyms.  They said it’s about peoples’ overall health and conditioning.

This goes for people who now work from home and may be missing out on the exercise and walking they did at work before the pandemic.

“We want people to be active whether it’s at home or whether it’s here at the club, and that’s what’s kind of pushed us to expand our revenue options,” said Josh Bruning, manager of Signature Fitness in Naperville.

Bruning said gyms are offering online exercise classes, and there is a need to redefine what qualifies as a workout.

“I would encourage people to stay physically active because it’s going to help boost the immune system,” Bruning said.